Antares Pharma Earnings: Here’s Why Investors are Selling Shares Now

Antares Pharma (NASDAQ:ATRS) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 1.1%.

Antares Pharma Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.04 in the quarter versus EPS of $-0.03 in the year-earlier quarter.

Revenue: Rose 28.32% to $5.8 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Antares Pharma reported adjusted EPS loss of $0.04 per share. By that measure, the company missed the mean analyst estimate of $-0.03. It missed the average revenue estimate of $5.82 million.

Quoting Management: Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “I am pleased to report that Antares made significant progress on many fronts during the second quarter as we transition to a specialty pharmaceutical company. Our primary focus is on the OTREXUP™ commercialization planned for early 2014. We recently completed the recruitment of an experienced in-house sales and marketing team with significant ‘Big Pharma’ product launch experience in the rheumatology market segment.” Dr. Wotton continued, “We also progressed our QST program for Testosterone Replacement Therapy and anticipate dosing the first patients in this coming quarter, which keeps this program on track for a potential launch in 2016.”

Key Stats (on next page)…

Revenue increased 28.04% from $4.53 million in the previous quarter. EPS decreased to $-0.04 in the quarter versus EPS of $-0.03 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.03 to a loss $0.04. For the current year, the average estimate is a loss of $0.12, which is the same with that ninety days ago.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]